Document ID: chunk:federal_register_of_legislation:F2020L01393:reg:9:p2
Version: federal_register_of_legislation:F2020L01393
Segment Type: reg
Provision Reference: reg 9 (pt 2/2)
Character Range: 6343–8257

include spinal fusion, laminectomy and discectomy.
(15)      having a lumboperitoneal shunt at the affected site at the time of the clinical worsening of spinal adhesive arachnoiditis;
(16)      having a myelogram involving an injection of oil-soluble intrathecal radiological contrast agent before the clinical worsening of spinal adhesive arachnoiditis;
(17)      having a myelogram involving an injection of water-soluble intrathecal radiological contrast agent from the specified list of radiological contrast agents within the ten years before the clinical worsening of spinal adhesive arachnoiditis;
Note: specified list of radiological contrast agents is defined in the Schedule 1 - Dictionary.
(18)      having an injection of Thorotrast (thorium dioxide suspension) into the subarachnoid space before the clinical worsening of spinal adhesive arachnoiditis;
(19)      having an in situ intrathecal drug delivery system at the affected site at the time of the clinical worsening of spinal adhesive arachnoiditis;
(20)      having intrathecal injection of methotrexate or cytosine arabinoside within the one year before the clinical worsening of spinal adhesive arachnoiditis;
(21)      having intrathecal injection of radioactive gold at the affected site before the clinical worsening of spinal adhesive arachnoiditis;
(22)      having an infection from the specified list of infections before the clinical worsening of spinal adhesive arachnoiditis;
Note: specified list of infections is defined in the Schedule 1 - Dictionary.
(23)      having a subarachnoid haemorrhage within the ten years before the clinical worsening of spinal adhesive arachnoiditis;
(24)      having a spinal subdural haematoma at the affected site within the two years before the clinical worsening of spinal adhesive arachnoiditis;
(25)      inability to obtain appropriate clinical management for spinal adhesive arachnoiditis.